Replies to post #158554 on Biotech Values

[jq1234]

Of course. I am quite impressed with the result. Normally larger ph3 trial can't replicate very small ph2 trial result, but here produces almost identical DRR, very consistent. DRR along with immune response might be able to deliver OS secondary endpoint as well.